Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib with Trastuzumab and Chemotherapy in HER2+ Breast Cancer
NCT04481932Phase 2Recruiting
- Sponsor
- Peking University
- Start
- Jul 2020
- Primary completion
- Jun 2022
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of pyrotinib in HER2-positive breast cancer, sponsored by Peking University. Started Jul 2020; status: recruiting.
02
Drugs
pyrotinib
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT04481932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04481932.